|
- AstraZeneca Discloses AZD2389, a Reversible Covalent Inhibitor of FAP . . .
AstraZeneca’s AZD2389 was developed from prior reversible covalent FAP inhibitors through a focus on improving binding kinetics and eliminating AO metabolism AZD2389’s ADME-PK and safety profiles supported a detailed 29-week study of MASH in NHPs, which showed positive effects The compound has now progressed to a Ph
- Fibroblast activation protein activated antifibrotic peptide delivery . . .
FAP-specific activation of PRL would be crucial for focusing the effects of melittin on target fibrotic cells and minimizing possible side effects of melittin in the bloodstream
- Found in Translation – Fibrosis in Metabolic Dysfunction-Associated . . .
MASH is characterized by steatosis, hepatocyte ballooning, lobular inflammation, and fibrosis Among these features, the extent of fibrosis is the strongest predictor of patient mortality, and is therefore the focus of drug development efforts (13-16)
- FGF21 agonists: An emerging therapeutic for metabolic dysfunction . . .
In this review, we summarise preclinical and clinical data from FGF21 analogues for MASH and explore additional potential therapeutic indications FGF21 analogues possess a “directly” acting antifibrotic mechanism of action, reducing fibrogenesis rapidly after treatment starts, with significant regression of fibrosis after 24 weeks’ treatment
- AZD2389 AstraZeneca - LARVOL DELTA - delta. larvol. com
A SMALL MOLECULE INHIBITOR OF FIBROBLAST ACTIVATION PROTEIN (FAP) BLOCKS ENZYMATIC ACTIVITY AND IMPROVES LIVER HISTOPATHOLOGY IN CYNOMOLGUS MONKEYS WITH MASH AND F1 F2 FIBROSIS (AASLD 2024) - " We have developed a potent oral FAP inhibitor AZD2389, which blocks the cleavage of human a2-AP, FGF21 and collagens ex vivo To our knowledge, this
- FAP inhibitor AZD-2389 is a strong candidate for MASH treatment
Astrazeneca plc recently presented new results on their research regarding their oral small-molecule FAP inhibitor, AZD-2389, as a candidate drug for treating MASH
- Clinical Trials on Liver Fibrosis - ICH GCP
FibroScan (VCTE) ultrasound imaging will measure a participant's level of LSM (liver stiffness), CAP (amount of fat in the liver), and or SSM (spleen stiffness) This is where you will find people and organizations involved with this study
- A Phase 2a, Randomised, Single-blind, Placebo-controlled Study to . . .
A Phase 2a, Randomised, Single-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics and Explore the Pharmacodynamic Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis
|
|
|